Noemi Puig

Salamanca, CL 37007, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 163 publications

Measurable residual disease in myeloma: a MyRiaD of findings.

Measurable residual disease in myeloma: a MyRiaD of findings.

Journal: Blood

Published: June 04, 2026

How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care.

How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care.

Journal: Cancers

Published: March 17, 2026

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

Journal: Blood

Published: March 02, 2026

Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.

Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.

Journal: British journal of haematology

Published: February 26, 2026

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Journal: HemaSphere

Published: December 23, 2025

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Journal: Blood advances

Published: September 26, 2025

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Journal: Blood advances

Published: September 26, 2025

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances

Published: September 18, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances

Published: September 18, 2025

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

Journal: HemaSphere

Published: August 21, 2025

Showing 1-12 of 163

Last Updated: 09/26/2026